Feature Channels: Transplantation

• share
• favorite_border

Um homem pode piscar, engolir, sorrir e respirar pelo nariz pela primeira vez em uma década, graças a um transplante facial realizado na Mayo Clinic. Esse procedimento complexo e transformador destaca a equipe cirúrgica multidisciplinar altamente capacitada da Mayo Clinic, que oferece esperança aos pacientes com necessidades médicas complexas.

• share
• favorite_border

Un hombre puede parpadear, tragar, sonreír y respirar por la nariz por primera vez en una década, gracias a un trasplante facial realizado en Mayo Clinic. Este procedimiento complejo y transformador destaca al equipo quirúrgico multidisciplinario altamente capacitado de Mayo Clinic, que ofrece esperanza a los pacientes con necesidades médicas complejas.

• share
• favorite_border

A Michigan man can blink, swallow, smile and breathe through his nose for the first time in a decade thanks to a face transplant performed at Mayo Clinic. This transformative and complex procedure underscores Mayo Clinic's skilled multidisciplinary surgical team who provide hope to patients with complex medical needs.

• share
• favorite_border

Heart muscle cells grown from stem cells show promise in monkeys with a heart problem that typically results from a heart defect sometimes present at birth in humans, according to new research from the University of Wisconsin–Madison and Mayo Clinic.

• share
• favorite_border

Fecal Microbiota Transplantation for Childhood Constipation and More in the November Issue of AJG

• share
• favorite_border

The article, Safety of Kidney Transplantation from Donors with HIV, details findings supporting HIV-to-HIV kidney transplants as safe and just as effective as those using organs from donors without HIV.

• share
• favorite_border

Lurie Children’s surpassed a hospital record in its recent fiscal year by performing a record 140 pediatric transplants, including, heart, kidney, liver and stem cell. 

• share
• favorite_border

In a novel study that identified male chromosome genetic material in the intestines of female patients undergoing fecal transplants, researchers at Johns Hopkins Medicine say they have significantly expanded scientific understanding of how some of these transplants may succeed and work.

• share
• favorite_border

Ivan Maillard, MD, PhD, has been named Head of the Division of Hematologic Malignancies within the Department of Medicine at Memorial Sloan Kettering Cancer Center (MSK).

• share
• favorite_border

A new international trial is investigating the efficacy and safety of gene therapy in patients with Hurler syndrome and will compare results of gene therapy against BMT which is the current standard of care. UCSF Benioff Children’s Hospitals are among three sites in the U.S. and seven in the world now enrolling patients for the clinical trial.

• share
• favorite_border

Dr. Roy-Chaudhury will head up an organization—with nearly 21,000 health professionals representing 140 countries—dedicated to leading the fight against kidney diseases.

• share
• favorite_border

For kidney transplant recipients experiencing antibody-mediated rejection, the current standard of care involves removing donor-specific antibodies (DSAs) through plasmapheresis (PLEX)—a procedure that removes antibodies from the plasma portion of the blood. Results from a recent clinical trial reveal that an investigational drug called imlifidase, which cleaves and inactivates the type of antibodies that include DSAs, is more effective than PLEX. The research will be presented at ASN Kidney Week 2024 October 23–27.

• share
• favorite_border

Chronic active antibody-mediated rejection (caAMR) is a common cause of allograft loss after transplantation, with no approved therapies. Clazakizumab, a monoclonal antibody that targets the inflammatory cytokine interleukin-6 (IL-6), stabilized kidney transplant recipients’ kidney function in a phase 2 trial. Investigators now have data from a phase 3 trial with clazakizumab. The findings from the Phase 3 IMAGINE trial, the largest placebo-controlled study in kidney transplant recipients with caAMR, will be presented at ASN Kidney Week 2024 October 23– 27.

• share
• favorite_border

IgA nephropathy (IgAN) is an autoimmune kidney disease driven by immune cells that express a protein called CD38 on their surface. A recent Phase 2 trial revealed that felzartamab, an investigational anti-CD38 monoclonal antibody, helps to reduce proteinuria and maintain patients’ kidney function. Investigators evaluated the molecular mechanisms underlying felzartamab’s potential efficacy in IgAN. The findings will be presented at ASN Kidney Week 2024 October 23– 27.

• share
• favorite_border

Glucagon-like peptide-1-receptor agonists (GLP-1RA) are medications that are increasingly prescribed for patients with type 2 diabetes and congestive heart failure. Reports of GLP-1RA–associated acute kidney injury (AKI) have emerged, but the risk of GLP-1RA–associated AKI among patients on anti-cancer drugs is unclear. Surprisingly, new research suggests that taking GLP-1RA is not associated with an increased risk of AKI in patients receiving anti-cancer therapies. The findings will be presented at ASN Kidney Week 2024 October 23– 27.

• share
• favorite_border

Prior efforts to identify novel kidney biomarkers as risk factors for chronic kidney disease (CKD) progression have typically evaluated proteins individually, which limits their prognostic power. The National Institute of Diabetes and Digestive and Kidney Diseases’ (NIDDK’s) CKD Biomarkers Consortium of investigators recently developed and tested novel dimensions of kidney health by combining a set of 17 urine and plasma biomarkers that had been individually associated with CKD progression. The research will be presented at ASN Kidney Week 2024 October 23– 27.